ZEVRA THERAPEUTICS, INC. 8-K

What Happened
Zevra Therapeutics, Inc. (ZVRA) filed an 8-K on June 5, 2026 reporting results from its Annual Meeting of Stockholders held June 4, 2026. Of 59,114,850 shares outstanding as of the April 6, 2026 record date, 46,326,616 shares (78.37%) voted. Stockholders elected Douglas W. Calder and Corey Watton as Class II directors and ratified Ernst & Young LLP as the company’s independent registered public accounting firm. A proposed Charter amendment to phase out the classified board (declassify the Board) did not receive the required affirmative vote.

Key Details

• Record date/outstanding shares: 59,114,850 shares as of April 6, 2026; 46,326,616 shares voted (78.37% participation).
• Director elections (Proposal 1): Douglas W. Calder — For 25,754,763; Withheld 7,964,919; Broker non-votes 12,606,934. Corey Watton — For 29,878,306; Withheld 3,841,376; Broker non-votes 12,606,934. Both nominees were elected.
• Auditor ratification (Proposal 2): Ernst & Young LLP ratified — For 45,947,281; Against 234,753; Abstain 144,582.
• Charter amendment to declassify the Board (Proposal 3): For 32,557,653; Against 1,145,079; Abstain 16,950; Broker non-votes 12,606,934. The proposal required more than 66 2/3% of outstanding common stock and did not pass (For votes ≈55.1% of outstanding shares).

Why It Matters
The results confirm the company’s Board composition with two Class II directors seated and keep Ernst & Young as ZVRA’s auditor for fiscal 2026. The failed Charter amendment means the company’s classified board structure remains in place and directors will continue to serve staggered terms until any future change is approved. For investors, the outcome affects corporate governance (timing of board turnover) and affirms continuity in financial oversight through the ratified auditor.